Compare Alibaba Group (BABA) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alibaba Group vs Ginkgo Bioworks Holdings Inc — how do they compare? Alibaba Group trades at $124.98 (market cap $309.65B), while Ginkgo Bioworks Holdings Inc trades at $7.56 (market cap $515.15M). The key difference: Alibaba Group is far larger — about 601.1× Ginkgo Bioworks Holdings Inc's market cap, and Alibaba Group pays a 0.79% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| BABA | DNA | |
|---|---|---|
Market Cap | $309.65B | $515.15M |
Volume | 18,069,938 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $189.34 | $16.14 |
52-Week Low | $94.83 | $5.48 |
Enterprise Value | $304.43B | $617.10M |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alibaba (BABA) trades at $128.41, up 1.26% today, with a bullish technical signal and strong analyst support. Recent earnings misses contrast with solid fundamentals: revenue grew to $996.35B in 2025, net income margin expanded to 13.05%, and valuation ratios like P/E of 19.7 appear reasonable. The company announced a $1.05 dividend for H1-26 and faces multiple class-action lawsuits filed in August 2026, alleging securities fraud between June 2025 and June 2026.
Outlook is mixed: bullish analyst consensus (86% buy ratings) and a $195 price target suggest upside, but legal risks and earnings volatility pose headwinds. Investment opportunity hinges on AI growth and cloud strength, while risks include litigation outcomes and competitive pressures in China.
Ginkgo Bioworks (DNA) trades at $7.97, down 6.24% today, reflecting ongoing operational challenges. The company reported Q2 2026 revenue of $20 million, a 48% year-over-year decline, as it shifts focus to autonomous lab systems. Despite beating EPS expectations in two of the last three quarters, net losses remain substantial with a -219.6% margin. Technical indicators show bearish momentum with support at $7 and resistance at $9.
DNA faces significant headwinds with declining revenue and persistent losses, though analyst sentiment is mixed with 45% buy ratings. The pivot to new business lines creates uncertainty, while cash burn and competitive pressures present substantial risks. Upside depends on successful execution of the strategic shift and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alibaba Group
Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.
Read more on BABA →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
